Paraneoplastic syndrome

Y. Nakanishi, K. Takayama, N. Hara

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Treatment for the paraneoplastic syndrome associated with lung cancer was reviewed. The principle of the treatment of paraneoplastic syndrome is to control cancer as an underlying disease. Therefore, the standard therapy for Cushing's syndrome associated with lung cancer is surgical treatment if the tumor is operable. There is no standard therapy for Cushing's syndrome associated with advanced small-cell lung cancer. Metyrapone is used in combination with systemic chemotherapy. The effects of ketoconazole and octreotide are under investigation. To control hyponatremia due to the syndrome of inappropriate antidiuretic hormone secretion, fluid restriction is standard. When hyponatremia cannot be controlled with fluid restriction, demeclocycline can be used. For life-threatening hyponatremia, hypertonic saline with intravenous furosemide is administered under careful monitoring. Followed by hydration with saline, pamidronate is effective for the control of symptomatic hypercalcemia. Combined use of calcitonin facilitates rapid normalization of serum calcium for critically ill cases. Heparin is used for patients with recurrent episodes of thrombosis resulting from chronic disseminated intravascular coagulation, although the efficacy is controversial. Thrombocytes and coagulation factors are combined with heparin for patients with uncontrollable bleeding, although the efficacy is not established.

Original languageEnglish
Pages (from-to)445-450
Number of pages6
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume24 Suppl 3
Publication statusPublished - Oct 1997

Fingerprint

Paraneoplastic Syndromes
Hyponatremia
pamidronate
Cushing Syndrome
Heparin
Lung Neoplasms
Demeclocycline
Inappropriate ADH Syndrome
Therapeutics
Metyrapone
Ketoconazole
Blood Coagulation Factors
Octreotide
Disseminated Intravascular Coagulation
Furosemide
Small Cell Lung Carcinoma
Calcitonin
Hypercalcemia
Critical Illness
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Nakanishi, Y., Takayama, K., & Hara, N. (1997). Paraneoplastic syndrome. Gan to kagaku ryoho. Cancer & chemotherapy, 24 Suppl 3, 445-450.

Paraneoplastic syndrome. / Nakanishi, Y.; Takayama, K.; Hara, N.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 24 Suppl 3, 10.1997, p. 445-450.

Research output: Contribution to journalReview article

Nakanishi, Y, Takayama, K & Hara, N 1997, 'Paraneoplastic syndrome', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 24 Suppl 3, pp. 445-450.
Nakanishi Y, Takayama K, Hara N. Paraneoplastic syndrome. Gan to kagaku ryoho. Cancer & chemotherapy. 1997 Oct;24 Suppl 3:445-450.
Nakanishi, Y. ; Takayama, K. ; Hara, N. / Paraneoplastic syndrome. In: Gan to kagaku ryoho. Cancer & chemotherapy. 1997 ; Vol. 24 Suppl 3. pp. 445-450.
@article{9fa311f7ec6840d7bf7228d9e98308cb,
title = "Paraneoplastic syndrome",
abstract = "Treatment for the paraneoplastic syndrome associated with lung cancer was reviewed. The principle of the treatment of paraneoplastic syndrome is to control cancer as an underlying disease. Therefore, the standard therapy for Cushing's syndrome associated with lung cancer is surgical treatment if the tumor is operable. There is no standard therapy for Cushing's syndrome associated with advanced small-cell lung cancer. Metyrapone is used in combination with systemic chemotherapy. The effects of ketoconazole and octreotide are under investigation. To control hyponatremia due to the syndrome of inappropriate antidiuretic hormone secretion, fluid restriction is standard. When hyponatremia cannot be controlled with fluid restriction, demeclocycline can be used. For life-threatening hyponatremia, hypertonic saline with intravenous furosemide is administered under careful monitoring. Followed by hydration with saline, pamidronate is effective for the control of symptomatic hypercalcemia. Combined use of calcitonin facilitates rapid normalization of serum calcium for critically ill cases. Heparin is used for patients with recurrent episodes of thrombosis resulting from chronic disseminated intravascular coagulation, although the efficacy is controversial. Thrombocytes and coagulation factors are combined with heparin for patients with uncontrollable bleeding, although the efficacy is not established.",
author = "Y. Nakanishi and K. Takayama and N. Hara",
year = "1997",
month = "10",
language = "English",
volume = "24 Suppl 3",
pages = "445--450",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

}

TY - JOUR

T1 - Paraneoplastic syndrome

AU - Nakanishi, Y.

AU - Takayama, K.

AU - Hara, N.

PY - 1997/10

Y1 - 1997/10

N2 - Treatment for the paraneoplastic syndrome associated with lung cancer was reviewed. The principle of the treatment of paraneoplastic syndrome is to control cancer as an underlying disease. Therefore, the standard therapy for Cushing's syndrome associated with lung cancer is surgical treatment if the tumor is operable. There is no standard therapy for Cushing's syndrome associated with advanced small-cell lung cancer. Metyrapone is used in combination with systemic chemotherapy. The effects of ketoconazole and octreotide are under investigation. To control hyponatremia due to the syndrome of inappropriate antidiuretic hormone secretion, fluid restriction is standard. When hyponatremia cannot be controlled with fluid restriction, demeclocycline can be used. For life-threatening hyponatremia, hypertonic saline with intravenous furosemide is administered under careful monitoring. Followed by hydration with saline, pamidronate is effective for the control of symptomatic hypercalcemia. Combined use of calcitonin facilitates rapid normalization of serum calcium for critically ill cases. Heparin is used for patients with recurrent episodes of thrombosis resulting from chronic disseminated intravascular coagulation, although the efficacy is controversial. Thrombocytes and coagulation factors are combined with heparin for patients with uncontrollable bleeding, although the efficacy is not established.

AB - Treatment for the paraneoplastic syndrome associated with lung cancer was reviewed. The principle of the treatment of paraneoplastic syndrome is to control cancer as an underlying disease. Therefore, the standard therapy for Cushing's syndrome associated with lung cancer is surgical treatment if the tumor is operable. There is no standard therapy for Cushing's syndrome associated with advanced small-cell lung cancer. Metyrapone is used in combination with systemic chemotherapy. The effects of ketoconazole and octreotide are under investigation. To control hyponatremia due to the syndrome of inappropriate antidiuretic hormone secretion, fluid restriction is standard. When hyponatremia cannot be controlled with fluid restriction, demeclocycline can be used. For life-threatening hyponatremia, hypertonic saline with intravenous furosemide is administered under careful monitoring. Followed by hydration with saline, pamidronate is effective for the control of symptomatic hypercalcemia. Combined use of calcitonin facilitates rapid normalization of serum calcium for critically ill cases. Heparin is used for patients with recurrent episodes of thrombosis resulting from chronic disseminated intravascular coagulation, although the efficacy is controversial. Thrombocytes and coagulation factors are combined with heparin for patients with uncontrollable bleeding, although the efficacy is not established.

UR - http://www.scopus.com/inward/record.url?scp=0031253361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031253361&partnerID=8YFLogxK

M3 - Review article

C2 - 9369921

AN - SCOPUS:0031253361

VL - 24 Suppl 3

SP - 445

EP - 450

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

ER -